Woodline Partners’s LENZ Therapeutics LENZ Stock Holding History

Woodline Partners’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$568K	Hold	100,000	–	–	﹤0.01%	961
2026 Q1	$915K	Hold	100,000	–	–	﹤0.01%	896
2025 Q4	$1.6M	Buy	+100,000	New	+$2.91M	0.01%	799
2022 Q3	–	Sell	-42,862	Closed	-$825K	–	836
2022 Q2	$825K	Hold	42,862	–	–	0.01%	533
2022 Q1	$1.53M	Hold	42,862	–	–	0.02%	413
2021 Q4	$3.73M	Hold	42,862	–	–	0.05%	325
2021 Q3	$4.92M	Sell	42,862 -1,384	-3%	-$205K	0.08%	254
2021 Q2	$9.52M	Buy	+44,246	New	+$7.71M	0.18%	139

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Woodline Partners's LENZ Position: Q2 2026 in Review

Woodline Partners held its LENZ Therapeutics (LENZ) position steady in Q2 2026 at 100,000 shares worth $568K. The position accounts for ﹤0.01% of the portfolio, ranked #961.

Woodline Partners first reported a position in LENZ in Q2 2021 and has held it in 8 quarters since. The position peaked at $9.52M in Q2 2021. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

Woodline Partners held 100,000 shares of LENZ Therapeutics worth $568K as of Q2 2026.
Woodline Partners left its LENZ Therapeutics share count unchanged in Q2 2026.
LENZ Therapeutics made up ﹤0.01% of Woodline Partners's portfolio in Q2 2026, its #961 holding.
Woodline Partners first reported a position in LENZ Therapeutics in Q2 2021 and has held it in 8 quarters since.
Woodline Partners's LENZ Therapeutics position peaked at $9.52M in Q2 2021.
144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.